EFM
E Fund Management Portfolio holdings
AUM
$2.1B
1-Year Return
23.31%
This Quarter Return
-2.75%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$1.99B
AUM Growth
+$45.8M
(+2.4%)
Cap. Flow
+$228M
Cap. Flow
% of AUM
11.45%
Top 10 Holdings %
Top 10 Hldgs %
56.29%
Holding
416
New
63
Increased
249
Reduced
78
Closed
21
Top Buys
| 1 |
Apple
AAPL
|
$42.1M |
| 2 |
NVIDIA
NVDA
|
$37.1M |
| 3 |
Microsoft
MSFT
|
$36.3M |
| 4 |
Amazon
AMZN
|
$13M |
| 5 |
Broadcom
AVGO
|
$12.2M |
Top Sells
| 1 |
Pinduoduo
PDD
|
$37.5M |
| 2 |
Futu Holdings
FUTU
|
$13.8M |
| 3 |
TSMC
TSM
|
$13.5M |
| 4 |
Applied Materials
AMAT
|
$7.01M |
| 5 |
Full Truck Alliance
YMM
|
$4.09M |
Sector Composition
| 1 | Technology | 40.04% |
| 2 | Consumer Discretionary | 27.82% |
| 3 | Communication Services | 8.98% |
| 4 | Healthcare | 6.75% |
| 5 | Financials | 5.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
BioCryst Pharmaceuticals
BCRX
$1.74B
| $125K | 0.01% |
16,612
-7,226
| -30% | -$54.3K |
|
377
Ford
F
$46.7B
| $101K | 0.01% |
+10,208
| New | +$101K |
|
378
ImmunityBio
IBRX
$2.27B
| $99.6K | 0.01% |
38,900
+9,622
| +33% | +$24.6K |
|
379
Emergent Biosolutions
EBS
$404M
| $97.9K | ﹤0.01% |
+10,238
| New | +$97.9K |
|
380
Kura Oncology
KURA
$713M
| $89.7K | ﹤0.01% |
+10,301
| New | +$89.7K |
|
381
Cogent Biosciences
COGT
$1.82B
| $88.8K | ﹤0.01% |
+11,380
| New | +$88.8K |
|
382
Humacyte
HUMA
$226M
| $82.5K | ﹤0.01% |
16,345
+476
| +3% | +$2.4K |
|
383
Altimmune
ALT
$334M
| $80.5K | ﹤0.01% |
11,159
+1,149
| +11% | +$8.28K |
|
384
Annexon
ANNX
$238M
| $79.2K | ﹤0.01% |
15,447
+4,086
| +36% | +$21K |
|
385
Ironwood Pharmaceuticals
IRWD
$188M
| $74.2K | ﹤0.01% |
16,746
-8,739
| -34% | -$38.7K |
|
386
Relay Therapeutics
RLAY
$710M
| $72.7K | ﹤0.01% |
17,654
+6,104
| +53% | +$25.1K |
|
387
Allogene Therapeutics
ALLO
$255M
| $55.4K | ﹤0.01% |
25,992
+5,629
| +28% | +$12K |
|
388
Erasca
ERAS
$457M
| $37.2K | ﹤0.01% |
14,838
-79
| -0.5% | -$198 |
|
389
Sana Biotechnology
SANA
$752M
| $36.2K | ﹤0.01% |
22,202
+1,612
| +8% | +$2.63K |
|
390
Arbutus Biopharma
ABUS
$805M
| $34K | ﹤0.01% |
+10,385
| New | +$34K |
|
391
Savara
SVRA
$643M
| $31.9K | ﹤0.01% |
10,399
-403
| -4% | -$1.24K |
|
392
Taysha Gene Therapies
TSHA
$917M
| $30.9K | ﹤0.01% |
+17,844
| New | +$30.9K |
|
393
Sangamo Therapeutics
SGMO
$165M
| $25.4K | ﹤0.01% |
+24,853
| New | +$25.4K |
|
394
Akebia Therapeutics
AKBA
$785M
| $24.2K | ﹤0.01% |
+12,716
| New | +$24.2K |
|
395
Scilex Holding
SCLX
$159M
| $13.4K | ﹤0.01% |
898
| – | – |
|
396
Agios Pharmaceuticals
AGIO
$2.09B
| – | – |
-5,751
| Closed | -$256K |
|
397
Apogee Therapeutics
APGE
$2.26B
| – | – |
-3,506
| Closed | -$206K |
|
398
Applied Therapeutics
APLT
$68.2M
| – | – |
-10,232
| Closed | -$87K |
|
399
Arrowhead Research
ARWR
$4.02B
| – | – |
-11,438
| Closed | -$222K |
|
400
Beam Therapeutics
BEAM
$2.11B
| – | – |
-12,020
| Closed | -$294K |
|